drugset / Trial / NCT02075008

Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

NCT02075008

Phase 2 Terminated 270 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.

Timeline

Start
2014-03-27
Primary completion
2016-03-22
Completion
2016-03-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Ligelizumab Monoclonal antibody 240 mg Subcutaneous

Indications